AKRO — Akero Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $1.52bn
- $992.16m
- 40
- 26
- 62
- 38
Annual balance sheet for Akero Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 136 | 268 | 188 | 351 | 550 |
| Prepaid Expenses | |||||
| Total Current Assets | 138 | 271 | 194 | 355 | 560 |
| Net Property, Plant And Equipment | — | 1.79 | 1.55 | 1.29 | 1.03 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 138 | 273 | 196 | 357 | 580 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 9.37 | 13.1 | 25.1 | 19.1 | 19.1 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 9.39 | 14.6 | 26.4 | 30 | 45 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 129 | 259 | 169 | 327 | 535 |
| Total Liabilities & Shareholders' Equity | 138 | 273 | 196 | 357 | 580 |
| Total Common Shares Outstanding |